Maintenance pharmacotherapy for opioid dependence and SF-36 health status: A comparison with general population norms and other chronic disorders

Addictive Disorders and their Treatment

Volumn 5, Issue 4, 2006, Pages 155-164

  O'Brien, Susannah ^a,f   Mattick, Richard P ^a   White, Jason ^b,c,f   Breen, Courtney ^a,f   Kimber, Jo ^a,f   Ritter, Alison ^d,f   Lintzeris, Nicholas ^e,f   Ali, Robert ^f   Bammer, Gabriele ^f   Bell, James ^f   Digiusto, Erol ^f   Doran, Chris ^f   Gates, Jenny ^f   Glasgow, Nicholas ^f   Gospodarevskaya, Elena ^f   Harris, Anthony ^f   Hawken, Lynn ^f   Henderson, Nicky ^f   Marshall, Phil ^f   Quigley, Allan ^f   Saunders, John B ^f   Shakeshaft, Anthony ^f   Shanahan, Marian ^f   Shearer, James ^f   more..

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Drug & Alcohol Services South Australia   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d TURNING POINT ALCOHOL AND DRUG CENTRE   (Australia)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f NONE

Author keywords

Maintenance treatment; NEPOD; Opioid dependence; Quality of life; SF 36

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; METHADONE; NALTREXONAZINE;

ADULT; ARTICLE; AUSTRALIA; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVIDENCE BASED PRACTICE; FEMALE; FOLLOW UP; HEALTH STATUS; HEALTH SURVEY; HEROIN DEPENDENCE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; SHORT FORM 36; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

EID: 33845396489     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.adt.0000210078.99735.27     Document Type: Article

References (31)

1. McLellan AT, Lewis DC, O'Brien CP, et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689-1695.
2. O'Brien CP, McLellan AT. Myths about the treatment of addiction. Lancet. 1996;347:237-240.
3. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet. 1999;353:221-226.
4. Mattick RP, Ali R, White JM, et al. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction. 2003;98:441-452.
5. Torrens M, Domingo-Salvany A, Alonso J, et al. Methadone and quality of life [Letter]. Lancet. 1999;353:1101.
6. Ware JE, Sherbourne CD. The MOS 36-item short form health survey (SF-36) I. conceptual framework and item selection. Med Care. 1992;30:473-483.
7. Ware JE, Snow KK, Kosinski M, et al. SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center; 1993.
8. Ryan CF, White JM. Health status at entry to methadone maintenance treatment using the SF-36 health survey questionnaire. Addiction. 1996;91:39-45.
9. Digiusto E, Mattick RP, Kimber J, et al. National evaluation of pharmacotherapies for opioid dependence - why have we done it? Drug Alcohol Rev. 2001;20:139-141.
10. Digiusto E, Shakeshaft A, Ritter A, et al. and the NEPOD Research Group. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction. 2004;99:450-460.
11. Digiusto E, Lintzeris N, Breen C, et al. and the NEPOD Research Group. Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. Addict Behav. 2005;30:443-456.
12. Shanahan MD, Doran CM, Digiusto E, et al. and the NEPOD Research Group. A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addict Behav. 2006;31:371-387.
13. Saunders J, Jones R, Dean A, et al. Comparison of rapid opiate detoxification and naltrexone with methadone maintenance in the treatment of opiate dependence: a randomised controlled trial. Paper presented at the combined Australian Professional Society on Alcohol and Other Drugs (APSAD) and National Methadone Conference, Sydney; 29-31 October, 2001.
14. McGregor C, Ali R, White JM, et al. A comparison of antagonist- precipitated withdrawal under anesthesia to standard in-patient withdrawal as a pre-cursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months. Drug Alcohol Dependence. 2002;68:5-14.
15. Tucker T, Ritter A, Maher C, et al. Naltrexone maintenance for heroin dependence: uptake, attrition and retention. Drug Alcohol Rev. 2004;23:299-309.
16. Lintzeris N, Ritter A, Panjari M, et al. Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. Am J Addict. 2004;13:S29-S41.
17. Ritter AJ, Lintzeris N, Clark N, et al. A randomized trial comparing levo-alpha acetylmethadol with methadone maintenance for patients in primary care settings in Australia. Addiction. 2003;98:1605-1613.
18. Rea F, Bell JR, Young MR, et al. A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence. Drug Alcohol Dependence. 2004;75:79-88.
19. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston: The Health Institute, New England Medical Center; 1994.
20. Sanson-Fisher RW, Perkins JJ. Adaptation and validation of the SF-36 Health Survey for use in Australia. J Clin Epidemiol. 1998;51:961-967.
21. Australian Bureau of Statistics. National Health Survey: SF-36 Population Norms, Australia 1995. Catalogue No. 4399.0. Canberra: Australian Bureau of Statistics; 1997.
22. Philipp M, Kohnen R, Hiller K- O. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. Br Med J. 1999;319:1534-1539.
23. Coulehan JL, Schulberg HC, Block MR, et al. Treating depressed primary care patients improves their physical, mental, and social functioning. Arch Internal Med. 1997;157:1113-1120.
24. Bobes J, Gutiérrez M, Gibert J, et al. Quality of life in schizophrenia: long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment. Eur Psychiatry. 1998;13:158-163.
25. Revicki DA, Genduso LA, Hamilton SH, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomised clinical trial. Qual Life Res. 1999;8:417-426.
26. Goddijn PPM, Bilo HJG, Feskens EJM, et al. Longitudinal study of glycaemic control and quality of life in patients with Type 2 diabetes mellitus referred for intensified control. Diabetic Med. 1999;16:23-30.
27. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. New Jersey: Lawrence Erlbaum; 1988.
28. Hall W. Rolleston revisited. Addiction. 2000;95:1273-1280.
29. Muldoon MF, Barger SD, Flory JD, et al. What are quality of life measurements measuring? Br Med J. 1998;316:542-545.
30. Torrens M, San L, Martinez A, et al. Use of the Nottingham Health Profile for measuring health status of patients in methadone maintenance treatment. Addiction. 1997;92:707-716.
31. Giacomuzzi SM, Riemer Y, Ertl M, et al. Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. Addiction. 2003;98:693-702.